Home / INCPF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does INCPF make money? Does INCPF have pricing power? What's the Earnings Whisper? Will INCPF profit more as the business scales? What is INCPF's management track record? Is INCPF's current price justified?

InnoCare Pharma Limited

$1.55 -$0.50 (-24.39%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$1.55

Day Range

$1.55$2.05

Year Range

$1.55$3.26

Market Cap

2.32B

AVG Volume

712

Trailing/Forward PE

25.54/9.55

PEG ratio

-0.95

Dividend Yield

Next Earnings Date

2026-11-16

Primary Exchange

Other OTC

Revenue (CNY)

INCPF Revenue (CNY) by year
Period	Revenue (CNY)
2025	2.36B
2024	1.01B
2023	734.31M

Net Income (CNY)

INCPF Net Income (CNY) by year
Period	Net Income (CNY)
2025	632.42M
2024	-440.63M
2023	-631.26M

Operating Income (CNY)

INCPF Operating Income (CNY) by year
Period	Operating Income (CNY)
2025	541.59M
2024	-451.05M
2023	-503.41M

EBITDA (CNY)

INCPF EBITDA (CNY) by year
Period	EBITDA (CNY)
2025	574.76M
2024	-456.9M
2023	-600.23M

Cash Flows (CNY)

INCPF Cash Flows (CNY) by year
Period	Cash Flows (CNY)
2025	75.6M
2024	-443.78M
2023	-838.58M

EPS (CNY)

INCPF EPS (CNY) by year
Period	EPS (CNY)
2025	0.35
2024	-0.27
2023	-0.36

Expenses (CNY)

INCPF Expenses (CNY) by year
Period	Expenses (CNY)
2025	1.75B
2024	1.48B
2023	1.67B

Cash & Debt (CNY)

INCPF Cash & Debt (CNY) by year
Period	Cash & Debt (CNY)
2025	7.34B
2024	7.29B
2023	8.29B

Debt ratios

INCPF Debt ratios by year
Period	Debt ratios
2025	5.11
2024	5.86
2023	3.96

Margins

INCPF Margins by year
Period	Margins
2025	90.88%
2024	86.29%
2023	73.35%

Return on Capital

INCPF Return on Capital by year
Period	Return on Capital
2025	8.16%
2024	-6.53%
2023	-8.79%

Shares Outstanding

INCPF Shares Outstanding by year
Period	Shares Outstanding
2025	1.76B
2024	1.62B
2023	1.76B

Book Value Per Share (CNY)

INCPF Book Value Per Share (CNY) by year
Period	Book Value Per Share (CNY)
2025	4.4
2024	4.18
2023	4.07

Total Assets (CNY)

INCPF Total Assets (CNY) by year
Period	Total Assets (CNY)
2025	10.83B
2024	9.41B
2023	9.92B

PE Ratio

INCPF PE Ratio by year
Period	PE Ratio
Sep 26	25.48
Sep 26	25.48
Aug 26	25.54
Aug 26	25.52
Aug 26	25.6
Aug 26	25.62
Jul 26	25.64
Jul 26	25.71
Jul 26	25.73
Jul 26	25.73
Jul 26	25.78
Jun 26	29.36
Jun 26	29.23
Jun 26	29.21
Jun 26	29.22
May 26	29.22
May 26	29.34
May 26	29.41
May 26	29.37
May 26	29.49
Apr 26	29.52
Apr 26	29.44
Apr 26	29.49
Apr 26	29.74

Free Cash Flow Yield

INCPF Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	0.16%
Sep 26	0.16%
Aug 26	0.16%
Aug 26	0.16%
Aug 26	0.16%
Aug 26	0.16%
Jul 26	0.16%
Jul 26	0.16%
Jul 26	0.16%
Jul 26	0.16%
Jul 26	0.16%
Jun 26	0.41%
Jun 26	0.41%
Jun 26	0.41%
Jun 26	0.41%
May 26	0.41%
May 26	0.41%
May 26	0.41%
May 26	0.41%
May 26	0.41%
Apr 26	0.4%
Apr 26	0.41%
Apr 26	0.41%
Apr 26	0.4%
Mar 26	-0.75%
Mar 26	-0.75%
Mar 26	-0.75%
Mar 26	-0.75%
Feb 26	-0.75%
Feb 26	-0.57%
Feb 26	-0.57%
Feb 26	-0.56%
Jan 26	-0.56%
Jan 26	-0.56%
Jan 26	-0.56%
Jan 26	-0.56%
Jan 26	-0.56%
Dec 25	-1.11%
Dec 25	-1.06%
Dec 25	-1.06%
Dec 25	-1.06%
Nov 25	-1.06%
Nov 25	-1.05%
Nov 25	-0.97%
Nov 25	-0.97%
Oct 25	-0.69%
Oct 25	-0.69%
Oct 25	-0.68%
Oct 25	-0.68%
Oct 25	-0.69%
Sep 25	-0.7%
Sep 25	-0.7%
Sep 25	-0.7%
Sep 25	-0.7%
Aug 25	-0.7%
Aug 25	-0.7%
Aug 25	-0.69%
Aug 25	-0.69%
Aug 25	-0.69%
Jul 25	-0.7%
Jul 25	-0.7%
Jul 25	-0.7%
Jul 25	-0.7%
Jun 25	-1.18%
Jun 25	-1.18%
Jun 25	-1.17%
Jun 25	-1.17%
May 25	-1.17%
May 25	-1.17%
May 25	-1.17%
May 25	-1.16%
May 25	-1.16%
Apr 25	-1.16%
Apr 25	-1.15%
Apr 25	-1.16%
Apr 25	-1.16%
Mar 25	-1.48%
Mar 25	-1.48%
Mar 25	-1.48%
Mar 25	-1.48%
Feb 25	-1.47%
Feb 25	-1.48%
Feb 25	-1.48%
Feb 25	-1.47%
Jan 25	-1.48%
Jan 25	-1.48%
Jan 25	-1.47%
Jan 25	-1.46%
Jan 25	-1.47%
Dec 24	-2.22%
Dec 24	-2.22%
Dec 24	-2.23%
Dec 24	-2.23%
Nov 24	-2.24%
Nov 24	-2.24%
Nov 24	-2.24%

Price to Sales

INCPF Price to Sales by year
Period	Price to Sales
Sep 26	7.34
Sep 26	7.34
Aug 26	7.35
Aug 26	7.35
Aug 26	7.37
Aug 26	7.38
Jul 26	7.38
Jul 26	7.4
Jul 26	7.41
Jul 26	7.41
Jul 26	7.42
Jun 26	7.88
Jun 26	7.85
Jun 26	7.84
Jun 26	7.84
May 26	7.84
May 26	7.88
May 26	7.89
May 26	7.88
May 26	7.91
Apr 26	7.92
Apr 26	7.9
Apr 26	7.91
Apr 26	7.98
Mar 26	13.24
Mar 26	13.19
Mar 26	13.21
Mar 26	13.21
Feb 26	13.13
Feb 26	17.5
Feb 26	17.5
Feb 26	17.58
Jan 26	17.61
Jan 26	17.64
Jan 26	17.65
Jan 26	17.67
Jan 26	17.71
Dec 25	13.18
Dec 25	13.76
Dec 25	13.79
Dec 25	13.82
Nov 25	13.83
Nov 25	13.89
Nov 25	15.05
Nov 25	15.1
Oct 25	21.29
Oct 25	21.3
Oct 25	21.32
Oct 25	21.34
Oct 25	21.3
Sep 25	34.11
Sep 25	34.02
Sep 25	34.07
Sep 25	34.11
Aug 25	34.1
Aug 25	34.26
Aug 25	34.34
Aug 25	34.35
Aug 25	34.48
Jul 25	34.27
Jul 25	34.32
Jul 25	34.28
Jul 25	34.28
Jun 25	37.41
Jun 25	37.34
Jun 25	37.45
Jun 25	37.49
May 25	37.55
May 25	37.45
May 25	37.6
May 25	37.74
May 25	37.92
Apr 25	38
Apr 25	38.07
Apr 25	38.03
Apr 25	37.97
Mar 25	49.8
Mar 25	49.71
Mar 25	49.63
Mar 25	49.61
Feb 25	49.94
Feb 25	49.72
Feb 25	49.74
Feb 25	49.98
Jan 25	49.72
Jan 25	49.67
Jan 25	50.23
Jan 25	50.28
Jan 25	50.2
Dec 24	45.49
Dec 24	45.48
Dec 24	45.35
Dec 24	45.32
Nov 24	45.15
Nov 24	45.17
Nov 24	45.07

EV/EBITDA

INCPF EV/EBITDA by year
Period	EV/EBITDA
Sep 26	20.26
Sep 26	20.26
Aug 26	20.32
Aug 26	20.3
Aug 26	20.39
Aug 26	20.41
Jul 26	20.43
Jul 26	20.52
Jul 26	20.53
Jul 26	20.54
Jul 26	20.59
Jun 26	22.34
Jun 26	22.2
Jun 26	22.17
Jun 26	22.18
May 26	22.19
May 26	22.32
May 26	22.39
May 26	22.35
May 26	22.48
Apr 26	22.52
Apr 26	22.43
Apr 26	22.48
Apr 26	22.75

Price/Operating Cashflow

INCPF Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Sep 26	174.46
Sep 26	174.48
Aug 26	174.87
Aug 26	174.74
Aug 26	175.26
Aug 26	175.42
Jul 26	175.53
Jul 26	176.06
Jul 26	176.17
Jul 26	176.18
Jul 26	176.49
Jun 26	127.28
Jun 26	126.73
Jun 26	126.62
Jun 26	126.67
May 26	126.69
May 26	127.22
May 26	127.5
May 26	127.33
May 26	127.83
Apr 26	127.99
Apr 26	127.63
Apr 26	127.84
Apr 26	128.92

Price to Book

INCPF Price to Book by year
Period	Price to Book
Sep 26	2.5
Sep 26	2.5
Aug 26	2.5
Aug 26	2.5
Aug 26	2.51
Aug 26	2.51
Jul 26	2.51
Jul 26	2.52
Jul 26	2.52
Jul 26	2.52
Jul 26	2.53
Jun 26	2.39
Jun 26	2.38
Jun 26	2.38
Jun 26	2.38
May 26	2.38
May 26	2.39
May 26	2.4
May 26	2.4
May 26	2.41
Apr 26	2.41
Apr 26	2.4
Apr 26	2.41
Apr 26	2.43
Mar 26	2.83
Mar 26	2.82
Mar 26	2.82
Mar 26	2.82
Feb 26	2.81
Feb 26	3.74
Feb 26	3.74
Feb 26	3.76
Jan 26	3.76
Jan 26	3.77
Jan 26	3.77
Jan 26	3.78
Jan 26	3.79
Dec 25	2.59
Dec 25	2.71
Dec 25	2.71
Dec 25	2.72
Nov 25	2.72
Nov 25	2.73
Nov 25	2.96
Nov 25	2.97
Oct 25	4.19
Oct 25	4.19
Oct 25	4.19
Oct 25	4.2
Oct 25	4.19
Sep 25	6.17
Sep 25	6.16
Sep 25	6.17
Sep 25	6.17
Aug 25	6.17
Aug 25	6.2
Aug 25	6.22
Aug 25	6.22
Aug 25	6.24
Jul 25	6.2
Jul 25	6.21
Jul 25	6.21
Jul 25	6.21
Jun 25	5.6
Jun 25	5.59
Jun 25	5.6
Jun 25	5.61
May 25	5.62
May 25	5.6
May 25	5.63
May 25	5.65
May 25	5.67
Apr 25	5.69
Apr 25	5.7
Apr 25	5.69
Apr 25	5.68
Mar 25	6.56
Mar 25	6.55
Mar 25	6.54
Mar 25	6.54
Feb 25	6.58
Feb 25	6.55
Feb 25	6.55
Feb 25	6.59
Jan 25	6.55
Jan 25	6.55
Jan 25	6.62
Jan 25	6.63
Jan 25	6.61
Dec 24	5.12
Dec 24	5.12
Dec 24	5.1
Dec 24	5.1
Nov 24	5.08
Nov 24	5.08
Nov 24	5.07
May 23	5.31
May 23	5.27
May 23	5.23
May 23	5.2

No video analysis for this stock yet. Request one from our team.

News: INCPF

seekingalpha.com · 24 Aug 2026

InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript

reuters.com · 27 Jul 2026

China's Innocare's psoriasis drug meets main goal in late-stage trial

China-based Innocare Pharma said on ‌Monday the Phase III trial of fadeucravacitinib, an ⁠experimental treatment for moderate-to-severe plaque psoriasis, has met its primary endpoint.

globenewswire.com · 5 Jul 2026

InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China

BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare's in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease-cleavable linker.